Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Montelukast Intermediate. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN110903188A reveals a novel one-pot synthesis for tribromoneopentanol acetate using in-situ HBr generation, offering high purity and scalable manufacturing for pharmaceutical intermediates.
Patent CN115819300B enables high yield synthesis. Reduces toxic reagents. Reliable supply chain partner for pharmaceutical intermediates.
Discover the patented cyanide-free route for 1-mercaptomethylcyclopropyl acetic acid. Enhance supply chain safety and reduce manufacturing costs with scalable technology.
Patent CN112724082B details a cost-effective copper-catalyzed route for montelukast intermediates, offering superior purity and supply chain stability for global pharmaceutical manufacturers.
Patent CN103524408A details a high-yield aqueous synthesis of 7-chloroquinaldine using SDS and phosphomolybdic acid, offering significant cost and purity advantages for pharmaceutical manufacturing.
Patent CN101356158A details a robust Montelukast synthesis using stable thiolactone intermediates and activated cerium catalysis for superior purity and supply chain reliability.
Patent CN103554016B reveals enzymatic synthesis for high-purity API intermediates. Achieve substantial cost reduction and supply chain reliability with scalable green chemistry solutions.
Patent CN118421578A reveals high-efficiency carbonyl reductase for Montelukast intermediate. Offers cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN106928136B details graphene palladium cobalt catalysis for montelukast intermediate. Offers high yield and chiral selectivity for reliable pharmaceutical intermediate supply chains.
Patent CN106928136A reveals graphene palladium cobalt catalyst for Montelukast intermediate. Enhances purity and supply chain reliability for pharmaceutical manufacturing.
Patent CN103073492A details a green Ru-catalyzed transfer hydrogenation for Montelukast intermediates, offering significant cost reduction and supply chain reliability.
Patent CN104592110A reveals cost-effective chiral reduction for Montelukast intermediate ensuring high purity and scalable supply chain reliability for global pharmaceutical manufacturers
Novel nucleophilic substitution route for Montelukast intermediate. High optical purity, mild conditions, cost-effective manufacturing for global supply chains.
Advanced preparation process for Montelukast sodium intermediate via efficient sulfonylation and thiourea displacement. Delivers high purity and scalable manufacturing solutions.
Patent CN103420908A reveals a high-yield asymmetric hydrogenation route for Montelukast intermediates, offering significant cost reduction and supply chain reliability for API manufacturers.
Patent CN103467276B offers a safer route for Montelukast intermediates ensuring supply chain reliability and cost efficiency for pharmaceutical manufacturing partners globally.
Patent CN112624921A reveals a novel Grignard-based synthesis for 1-hydroxymethyl cyclopropyl acetic acid, offering significant cost reduction and safety improvements for Montelukast manufacturing.
Discover the novel 4-step synthesis of Montelukast Sodium intermediate via patent CN115710221A. Achieve high purity, reduced costs, and scalable supply chain solutions.
Novel 2-step synthesis of Montelukast intermediate via Wittig and Pd-coupling. Reduces cost and steps for API manufacturing.
Patent CN105541786B introduces a solid acid-catalyzed transketalization method enhancing yield and reducing supply chain complexity for Montelukast intermediates.